GlassScriptPhysician profile
Andrew S Cho
NPI 1225072481
$20,465.33
in general payments reported to CMS, 2019-2025
40 companies · $4,434 in 2025
The $4,434 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,939 · 2020: $2,143 · 2021: $4,680 · 2022: $2,574 · 2023: $2,127 · 2024: $1,568 · 2025: $4,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,617 · Long Term Medical Supply Or Device Loan: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,616.79 |
| Long Term Medical Supply Or Device Loan | $511.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,899.53 | 2019-2022 | |
| Abbvie INC. | $1,888.50 | 2022-2025 | Xen Glaucoma Treatment System, Alphagan P, Vuity |
| Kala Pharmaceuticals, INC. | $1,429.73 | 2021 | |
| Alcon Vision LLC | $1,413.79 | 2019-2025 | Verion, Tryptyr, Argos |
| Aerie Pharmaceuticals, INC. | $1,350.51 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $1,264.24 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $1,204.43 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $1,093.08 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,040.49 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $748.83 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $710.14 | 2019-2023 | Flarex |
| Nova Eye, INC. | $637.20 | 2024-2025 | |
| Ivantis, INC | $625.33 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $612.60 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $561.91 | 2021-2025 | Eylea Hd, Eylea |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $480.31 | 2025 | M22 |
| Novo Nordisk INC | $459.70 | 2021-2025 | Wegovy |
| Amgen INC. | $384.50 | 2023-2025 | Tepezza, Otezla, Repatha |
| Thea Pharma INC. | $254.23 | 2022-2025 | Iyuzeh |
| Akorn, INC. | $229.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.40 | 2021-2023 | Jardiance |
| Akorn Operating Company LLC | $217.33 | 2021 | |
| Astellas Pharma US INC | $206.71 | 2024-2025 | Izervay, Prograf |
| Oyster Point Pharma, INC. | $191.29 | 2023-2025 | Tyrvaya |
| Biotissue Holdings INC. | $161.40 | 2022-2023 | |
| Shire North American Group INC | $155.74 | 2019 | |
| Axsome Therapeutics, INC. | $148.48 | 2025 | Symbravo |
| Abbott Laboratories | $133.76 | 2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Horizon Therapeutics Plc | $102.13 | 2020-2023 | Tepezza |
| Glaukos Corporation | $92.82 | 2019-2021 | |
| Dompe US, INC. | $76.77 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $72.70 | 2025 | Vevye |
| Alimera Sciences, INC. | $30.11 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $29.73 | 2023 | Syfovre |
| Topcon Healthcare Solutions, INC. | $24.54 | 2019 | |
| Genentech USA, INC. | $22.80 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.